Author: [email protected]

GC Oncology’s $380M IPO Kickstarts 2024 Biotech Market

Posted on by [email protected]

The New Year has kicked off with a bang in biotech, as CG Oncology has completed the first initial public offering in the space for 2024. The cancer-focused biotech raised a whopping $380 million in its IPO on the Nasdaq, sailing past its initial target range of $181 million.

CG Oncology priced its shares at $19 apiece, above the $16-18 range it had set ahead of the IPO. The impressive deal is being viewed by many analysts and investors as a positive indicator that the biotech IPO market is rebounding in 2024 after a relatively slow 2023.

The robust demand for CG Oncology stock reflects renewed optimism and openness to investing in early-stage biotech companies, especially those with innovative science and strong leadership teams.

CG Oncology is developing a novel oncolytic virus therapy known as cretostimogene grenadenorepvec for the treatment of non-muscle invasive bladder cancer. Oncolytic viruses represent an exciting new approach in cancer treatment, wherein specially engineered viruses are able to infect and destroy cancer cells directly while also stimulating anti-tumor immune responses.

Cretostimogene grenadenorepvec is an adenovirus that has been engineered to replicate selectively in bladder cancer cells and stimulate the immune system by expressing granulocyte-macrophage colony-stimulating factor (GM-CSF). Early stage clinical data have shown promising signs of efficacy.

The company plans to use the IPO proceeds to fund a Phase 3 clinical trial of its lead candidate as well as earlier stage pipeline programs. Success in the Phase 3 study could support regulatory approval and commercialization.

CG Oncology was founded in 2018 by a veteran team of biotech entrepreneurs and scientists. The company pursued a pre-IPO crossover financing round in 2022, enabling it to build momentum heading into its public debut.

The IPO success places CG Oncology in a strong position to advance its pipeline. With the influx of capital, the company will be able to aggressively pursue its clinical development plans without relying heavily on external partners.

Moreover, the validation and visibility provided by being a public company can potentially help CG Oncology forge productive collaborations and access additional funding in the future.

Looking ahead, the positive investor response to CG Oncology seems likely to pave the way for more biotech IPOs in 2024. A robust IPO market provides fuel for innovation and discoveries that can transform patient lives.

The biotech sector sputtered in 2022, with only around 20 IPOs completed versus more than 50 in 2021. However, sentiment appears to be shifting, perhaps signaling sunnier days ahead.

In addition to favorable market conditions, biotech companies pursuing IPOs seem to be taking valuable lessons from 2022 by tightening focus on fundamentals like drug efficacy and visibility on clinical milestones.

Other than CG Oncology, a host of biotechs have already filed with SEC intentions to go public in 2024, spanning exciting areas like gene therapy, neurology, and synthetic biology.

With fresh capital and investor enthusiasm, the next generation of biotech companies can pursue ambitious goals to develop innovative medicines. More early-stage companies may also gain the funding needed to initiate or advance clinical trials.

CG Oncology’s big IPO pop reflects the right combination of cutting-edge science, unmet medical need, and strong leadership. This formula will likely be replicated by other emerging biotech stars in the making.

In all, the successful CG Oncology IPO kicks off 2024 as a promising year for biotech funding, innovation, and progress against once intractable diseases. Investors and industry observers will be tracking the IPO market closely through the year for signs of sustained momentum. If the appetite for compelling biotech stories persists, it could drive a much-needed renaissance helping to unlock new medical frontiers.

Mark your calendars! Don’t miss Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference April 17-18. This exclusive virtual event connects investors with 50 leading public biotech, healthcare services, and medical device companies.
Presenting company slots are available.

Meta and Microsoft Achieve $1 Trillion Milestones as AI Investments Pay Off

Posted on by [email protected]

Two of the biggest tech giants, Meta and Microsoft, recently hit major market cap milestones as part of the ongoing record rally in tech stocks.

Meta’s market cap surpassed the $1 trillion during intraday trading on January 24th, marking the first time the company reclaimed this valuation since 2021. Meta previously hit the $1 trillion mark in September 2021 at the height of its stock’s popularity.

Driving Meta’s soaring stock price is a nearly 200% surge over the past year, as CEO Mark Zuckerberg enacted cost-cutting that included laying off over 20,000 employees. After its stock plummeted to a six-year low in 2022, Zuckerberg has described 2023 as a “year of efficiency.”

Shareholders are bullish on Meta’s focus on expanding its position in artificial intelligence. Last week, Zuckerberg revealed the company is ramping up AI investments, procuring hundreds of thousands of high-powered AI chips from Nvidia. This signals Meta is spending billions to compete in the red-hot AI space.

On the same day Meta topped $1 trillion, Microsoft also briefly surpassed the $3 trillion mark during trading on January 24th. This comes around two weeks after Microsoft temporarily overtook Apple as the world’s most valuable company in mid-January. While Apple has since regained the top valuation spot, Microsoft remains hot on its heels.

Fueling Microsoft’s continued share price gains is optimism around the company’s AI initiatives. Microsoft stock is up over 7% year-to-date amid strong demand for AI capabilities, especially in generative AI.

Analysts predict Microsoft will post a solid earnings beat for its upcoming quarterly report, citing its leadership in enterprise-level AI as a key advantage. Microsoft seems poised to capitalize on the explosion of interest in AI technologies like ChatGPT.

AI Arms Race

The back-to-back market cap milestones from Meta and Microsoft highlight the massive investments pouring into artificial intelligence right now.

With breakout successes like ChatGPT demonstrating new possibilities for generative AI, tech giants are racing to stake their claims. The companies leading development of advanced AI stand to reap substantial rewards.

Both Meta and Microsoft are positioning themselves at the forefront of this AI arms race. In addition to its major chip purchases, Meta recently unveiled its own chatbot project, BlenderBot. Microsoft is integrating generative AI into Bing search and other offerings.

The tech world’s strike into AI looks poised to pay off based on the positive investor sentiment boosting Meta and Microsoft’s valuations. However, the AI hype cycle could eventually lead to a correction for these high-flying stocks.

For now, shareholders seem willing to bet on the transformative potential of artificial intelligence. And the tech giants pouring money into AI research appear ready to capitalize on this enthusiasm.

Big Tech Boosts Markets

Meta and Microsoft reaching new market cap heights also highlights the outsized impact of Big Tech on the broader stock market. The performance of tech stocks is a key factor driving indexes like the S&P 500 to record levels.

Despite some pockets of weakness, optimism around AI and other emerging technologies continues fueling upward momentum. The Nasdaq index, heavily weighted toward tech, rose over 12% in 2023 even as the overall market declined.

This dynamic shows no signs of changing in 2024. Tech stocks led markets higher to begin the year, with the Nasdaq up close to 10% in January as of this writing. Stocks like Meta and Microsoft hitting new milestones reflects their leadership in this rally.

However, extended runs by Big Tech raise risks of overheating and heighten their influence on market swings. With Apple, Microsoft, Amazon, Alphabet and other tech giants comprising over 20% of the S&P 500, their performance significantly impacts overall returns.

Nonetheless, bullish sentiment toward AI and other disruptive tech breakthroughs appears likely to keep lifting valuations. As giants like Meta and Microsoft position themselves to capitalize on these trends, their gravity on markets looks set to rise.

NAYA Biosciences Strengthens Pipeline Through Acquisition of Gene Therapy Asset

Posted on by [email protected]

NAYA Biosciences is expanding its clinical portfolio through the acquisition of an innovative gene therapy program from Florida Biotechnologies focused on treating rare mitochondrial diseases. This binding deal demonstrates NAYA’s strategy to rapidly build pipeline assets in high-potential areas like gene therapy.

NAYA has entered into a binding letter of intent to acquire Florida Biotechnologies for $20 million in NAYA shares, with potential milestone payments up to $5 million more. The deal specifically targets Florida Biotech’s clinical-stage gene therapy for Leber’s Hereditary Optic Neuropathy (LHON).

LHON is a rare mitochondrial genetic disease leading to progressive vision loss and blindness. There are currently no approved treatments. Florida Biotech’s AAV gene therapy aims to deliver functional copies of the mutated gene to restore cellular function.

Encouraging Safety Data

This therapeutic has already demonstrated encouraging safety data in a 28-patient Phase 1 trial conducted by Florida Biotech and the University of Miami’s Bascom Palmer Eye Institute. Building on this initial study, NAYA aims to accelerate Phase 2 development and provide early access to patients.

The therapy delivers the gene of interest inside an adeno-associated virus (AAV) vector containing a mitochondrial targeting sequence. This sequence enables delivery specifically to mitochondria, the key site of pathology in LHON and many other mitochondrial diseases.

Broad Applicability

While the lead indication is LHON, NAYA highlights this approach has potential for various mitochondrial orphan diseases. The platform’s strong intellectual property covers use of different AAV capsids and routes of administration.

This flexibility and the high unmet need enables a streamlined regulatory path, including Regenerative Medicine Advanced Therapy and priority review voucher opportunities. The technology has already received over $6 million in grant funding to date.

The asset aligns with NAYA’s focus on innovative regenerative medicine approaches with near-term clinical potential. Gene therapy represents a key component of NAYA’s strategy to build a pipeline addressing major unmet needs.

Expertise in Developing Gene Therapies

NAYA has extensive in-house expertise to advance the acquired AAV gene therapy through late-stage trials toward commercialization. For example, NAYA Chief Medical Officer Dr. Fred Grossman previously led development of the first approved gene therapy, Glybera, during his time at uniQure.

Florida Biotech co-founder Dr. Peter Kash also joins NAYA’s board, bringing over 36 years of biotech leadership experience, including developing and financing gene therapy pioneer Kite Pharma. This expertise will prove valuable for unlocking the platform’s full potential.

Execution of Broader Growth Strategy

NAYA Biosciences was formed earlier in 2023 through the merger of Clinigence Holdings and 4Front Biotech. This deal created a holding company structure to facilitate pipeline expansion through additional strategic acquisitions.

The Florida Biotechnologies program represents the next step in this growth strategy. NAYA plans to continue acquiring high-potential clinical assets to build a robust portfolio spanning gene therapy, oncology, fertility and other areas.

These efforts support NAYA’s overall mission of providing patients earlier access to transformative therapies. The company aims to take an entrepreneurial approach to aggressively advance new technologies through development.

Pending Merger to Unlock Public Markets

NAYA’s deal to acquire Florida Biotechnologies is contingent upon the completion of NAYA’s previously announced merger with fertility company INVO Bioscience, expected in Q1 2024.

The merger will create a publicly traded life sciences company under the INVO name, providing access to capital to support NAYA’s development programs and commercialization. The combined company is valued at over $100 million.

Conclusion

In summary, NAYA Bioscience’s move to acquire Florida Biotechnologies’ AAV gene therapy strengthens its pipeline and aligns with its strategy to focus on high-potential clinical assets. Leveraging its development expertise, NAYA is positioned to accelerate this innovative therapy toward commercialization and fill an important unmet need for patients with mitochondrial diseases.

Biotech Innovation: Emerging Cancer Vaccines and Investment Potential

Posted on by [email protected]

Cancer research is rapidly evolving thanks to innovative biotech companies utilizing cutting-edge technology like artificial intelligence. One company at the forefront of this biotech revolution is Evaxion Biotech, which is developing novel personalized cancer vaccines powered by its proprietary AI platform.

As highlighted in a recent company press release, Evaxion is expanding its cancer vaccine pipeline to target a new class of AI-discovered tumor antigens called endogenous retroviruses (ERVs). ERVs are remnants of ancient viruses in our DNA that are often abnormally activated in cancer cells, making them visible targets for cancer vaccines.

Evaxion’s focus on ERV-based vaccines represents a breakthrough, transformative concept in cancer treatment. The company’s AI technology allows for identification of the most relevant ERV targets from patient genomic data, enabling truly personalized cancer vaccines.

Such precision vaccines could provide solutions for cancer patients unresponsive to current immunotherapies like checkpoint inhibitors. Evaxion aims to expedite development of this personalized vaccine approach, with initial proof-of-concept studies beginning mid-2024.

This innovation exemplifies the vast potential of emerging biotech companies to disrupt the cancer treatment landscape. Smaller firms like Evaxion can leverage cutting-edge technology like AI to uncover completely new therapeutic targets and strategies.

Powered by AI-Driven Discovery

Evaxion’s pivot to ERV-based vaccines is powered by its proprietary AI platform, AI-Immunology. This technology integrates advanced computational models that can decode the complexity of the human immune system’s interaction with cancer.

AI-Immunology allows rapid prediction and design of novel immunotherapy candidates. This is lightyears beyond traditional vaccine discovery dependent on lengthy trial-and-error experiments.

Evaxion’s AI technology provides a holistic, personalized approach to identify the most relevant targets and optimal vaccine strategies for each patient. This is key for developing effective cancer immunotherapies against the incredible heterogeneity seen across tumors and patients.

AI-Immunology represents a scalable, adaptable platform that can be applied to infectious diseases as well. Evaxion is also pursuing viral and bacterial vaccines powered by its AI discovery engine.

Other emerging biotech firms are also investing in AI-driven drug development, including companies like Recursion Pharmaceuticals, Exscientia, Insitro, and Valo Health. The massive potential of AI is transforming biopharmaceutical R&D.

Accelerating Innovation

Evaxion aims to accelerate innovation of its AI-discovered cancer vaccines. As indicated in its recent press release, the company has already initiated preclinical ERV vaccine studies, with plans for early proof-of-concept data by mid-2024.

This represents a rapid timeline from discovery to initial validation, enabled by AI-Immunology’s predictive modeling capabilities. Evaxion notes there is already significant interest around its ERV vaccine concept, which may help attract partners and investment to further accelerate development.

The company’s expedited progress exemplifies the ability of emerging biotech firms to move quickly from ideas to validation. Unencumbered by legacy infrastructure, these agile startups can transition discoveries into the clinic at unprecedented speed.

Investment Commentary

Evaxion’s pioneering AI platform and progress on its cancer vaccine pipeline highlights the compelling investment opportunities in emerging biotech companies.

These small firms offer differentiated technologies like AI-Immunology that enable transformative innovation not easily captured within larger pharmaceutical companies. First-mover advantage allows rapid value creation.

However, biotech investment carries significant risk. Clinical failures remain high across the industry. Diversification across a basket of emerging firms helps mitigate risks.

For investors interested in growth opportunities in small-cap biotech companies, the upcoming Noble Capital Markets Virtual Conference on April 17-18th features presentations from emerging healthcare and biotech companies.

The conference provides access to executive management teams from over 50 public microcap companies in the biotech, healthcare, and medical devices sector. It represents an excellent opportunity for exposure to innovative companies shaping the future of healthcare.

Biotech Revolution

We are in the midst of a biotechnology revolution led by innovative emerging firms. New technologies like AI and genomic profiling are unlocking unprecedented insights into disease biology and enabling personalized therapeutics.

Evaxion’s focus on AI-powered cancer vaccines represents just one example of transformative innovation occurring in the biotech sector. Other areas of rapid progress include gene therapies, cell therapies, targeted oncology treatments, and more.

Driven by these technological breakthroughs, the pace of biopharmaceutical advancement today is unprecedented. Venture capital investment in U.S. biotech startups hit record levels in 2021, topping $30 billion across over 1,000 deals.

The industry is positioned for continued expansion as emerging firms translate discoveries into new medicines. For investors, the high-growth biotech sector warrants attention despite its inherent risks.

Careful selection of companies with differentiated technologies like Evaxion’s AI platform can yield exciting returns. Ongoing evaluation of clinical execution remains key, as early scientific promise must still translate to real-world efficacy.

Overall, the biotech arena offers fertile ground for investment in innovation. The upcoming Noble Capital Markets Virtual Healthcare Conference highlights the wealth of emerging firms driving the biotechnology revolution.

Inhibrx Sells Lead Asset INBRX-101 to Sanofi for Up to $2.2 Billion

Posted on by [email protected]

Biotechnology company Inhibrx announced today that it has entered into a definitive agreement to sell its lead therapeutic candidate, INBRX-101, to French pharmaceutical giant Sanofi in a deal valued at up to $2.2 billion.

INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) therapy being developed for the treatment of alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder that can cause severe lung and liver disease. Under the terms of the agreement, Sanofi will acquire Inhibrx through a merger in which Inhibrx shareholders will receive $30 per share in cash, a contingent value right (CVR) worth up to $5 per share, and one share in a new publicly traded company called Inhibrx Biosciences for every four shares of Inhibrx held.

Inhibrx Biosciences will retain all of Inhibrx’s pipeline assets and infrastructure outside of INBRX-101. This includes several early-stage therapeutic candidates such as INBRX-105 for solid tumors, INBRX-106 for hematologic malignancies, and INBRX-109 for conventional chondrosarcoma. The new company will receive $200 million in cash funding from Sanofi and begin trading publicly after the completion of the merger.

The total potential value of the upfront cash payment, CVR, and Inhibrx’s debt assumption implies an aggregate transaction value of approximately $2.2 billion. Inhibrx shareholders will also own 92% of the equity in the newly formed Inhibrx Biosciences, which will provide opportunities for future value creation.

The acquisition provides Sanofi with full rights to develop and commercialize INBRX-101 globally. The drug candidate is currently in a registrational Phase 2/3 trial evaluating its safety and efficacy in patients with AATD. Inhibrx believes INBRX-101 has multi-billion dollar peak sales potential if approved, which likely drove Sanofi’s interest in the asset.

Inhibrx’s innovative AAT therapy utilizes the company’s novel therapeutic protein engineering capabilities. INBRX-101 is designed to maintain the stability and activity of AAT, potentially enabling less frequent dosing than current AAT therapies. This next-generation approach could position INBRX-101 as a best-in-class treatment option for AATD.

The proposed transaction has been unanimously approved by the boards of directors of both companies and is expected to close in Q2 2024, subject to Inhibrx shareholder approval, regulatory clearances, and other customary closing conditions. Until then, it will be business as usual for Inhibrx as it continues developing its pipeline assets.

For Sanofi, the acquisition expands its portfolio in rare diseases while strengthening its capabilities in protein sciences and engineering. Adding INBRX-101 provides Sanofi with a promising late-stage candidate that can leverage its expertise and infrastructure in pulmonary diseases. Sanofi has been active on the deals front lately, including a recent $3.2 billion deal for Amunix Pharmaceuticals, as it refreshes its pipeline.

Meanwhile, the new Inhibrx Biosciences will emerge as an up-and-coming biotech with strong financial backing, a seasoned management team, and innovative technology platforms. The company will continue operating under the Inhibrx name and leadership. This strategic deal allows Inhibrx to unlock significant value from its lead program while retaining its other assets and resources to drive future growth.

The transaction is a win for both parties, providing Sanofi with a potential blockbuster drug and Inhibrx shareholders with an attractive return and ongoing upside through Inhibrx Biosciences. It demonstrates the broader trend of big pharma leveraging M&A to access innovative therapies from smaller biotech players. As Inhibrx’s programs advance, it will be interesting to see if Inhibrx Biosciences attracts buyout interest down the road. But for now, the company seems well-positioned to create value by advancing its earlier-stage pipeline.

Take a look at more emerging growth biotech companies by taking a look at Noble Capital Markets’ Senior Research Analyst Robert LeBoyer’s coverage universe.

Rotating Into Mining: The Overlooked Opportunity in Natural Resources

Posted on by [email protected]

In the investing world, money often rotates between different sectors over time. After a long period of technology stocks dominating, we may now be entering a new cycle where mining and natural resource stocks start to outperform other industries and sectors. There are several compelling reasons mining could be the next big thing for investors.

First, demand is soaring for the critical minerals and metals used in electric vehicles, batteries, and clean energy. Metals like lithium, nickel, cobalt, and copper are essential for manufacturing electric car batteries, solar panels, wind turbines, and other green technologies. With many countries pushing for faster adoption of EVs and renewable power, demand for these key minerals is skyrocketing. Major automakers have announced ambitious electric vehicle plans, which requires secure access to raw materials. This imbalance between booming demand and limited supply bodes well for mining firms.

Additionally, the pandemic exposed risks of relying on a few countries for critical minerals. It revealed the need for domestic mining capacity to ensure stable access to essential inputs like lithium. For instance, the U.S. aims to boost domestic production of strategic minerals and reduce dependence on China. The EU also has a new plan to secure rare earth supplies within Europe. This focus on mineral independence is a plus for miners in North America and Europe.

Rising inflation and gold prices also bolster the case for mining stocks. With central banks printing huge amounts of money, many investors see gold as an inflation hedge. This has helped push gold prices to an 8-month high around $1900/ounce. Higher inflation tends to lift gold and silver prices as people flock to hard assets. Many miners produce both precious metals alongside base metals. They benefit from rising gold and silver prices.

Additionally, gold often rises when risks are high, like the current Russia-Ukraine and Israel-Gaza crises. Its safe haven appeal attracts buyers during geopolitical tensions. Between high inflation and geopolitical uncertainty, the macroeconomic environment seems favorable for both precious metal and base metal prices. This could kickstart a broad recovery across the mining sector.

The recent wave of mergers and acquisitions in mining also signals a positive shift. . In November 2023, Newmont Corporation completed its acquisition of Newcrest Mining Limited to create a leading global gold mining company with robust copper production. Just this month, Rio Tinto announced an $825 million lithium project purchase to support its battery materials business. These deals indicate big miners are positioning to capitalize on the electric vehicle revolution. Other companies like Century Lithium Corp. aim to produce lithium for the electric vehicle and battery storage market.

Additionally, mining stocks have held up well compared to the broader market’s decline. The global lithium stock index has surged over 110% in the past year. Many mining stocks linked to EVs have shown resilience amidst the tech stock plunge. This relative strength highlights the bullish outlook for miners enabling the energy transition. Noble Capital Markets’ investment banker Francisco Penafiel shared that “In the recent past, battery minerals have been getting the attention from investors, especially  critical metals such as lithium and cobalt. However, base metals like copper and nickel should also gain a healthy traction from the investment community, narrowing the existing valuation gap for junior miners,  due to the expected increase in their market demand as those are essential in the creation process of more efficient battery technologies”.   

After years of underperformance, mining stocks also look attractive relative to potential growth. For instance, the price-to-earnings ratio for diversified mining giant Glencore is under 6x, a bargain compared to high-flying tech stocks. While mining is volatile, long-term investors could be rewarded handsomely for their patience. The time seems ripe for mining stocks to revert upward after years of neglect.

Of course, risks exist like policy changes, permitting issues, cost inflation, and ESG concerns. But the overarching trend toward electrification seems unstoppable. While mining is cyclical, we appear to be entering an upcycle driven by underinvestment in new supply and exploding demand for the minerals needed to power the green transition.

Noble Capital Markets’ Senior Research Analyst, Mark Reichman states, “Our outlook for the mining sector remains favorable, particularly for the precious metals mining sub-sector. We believe growing electrification among developed nations and increased infrastructure spending bodes well for the long-term outlooks for metals such as copper, lithium, rare earths, and nickel. We think M&A activity will continue as large mining, energy, car manufacturers, and battery makers seek to de-risk their long-term strategies by ensuring long-term supplies of raw materials.”

In summary, mining stocks check many important boxes right now – strong demand drivers, favorable macro conditions, M&A activity, and reasonable valuations after a prolonged slump. The long-overlooked mining space seems poised for a renaissance, offering investors exciting opportunities. The winds appear to be shifting in favor of mining stocks as we embark on the new year and beyond. After years stuck in the doldrums, mining finally looks set to retake the spotlight.

Take a moment to take a look at Haynes International, a leading developer, manufacturer, and marketer of technologically advanced, nickel and cobalt-based high-performance alloys.

Alphabet Ends Relationship with AI Training Firm Appen in Major Blow

Posted on by [email protected]

Tech giant Alphabet has decided to terminate its contractual relationship with Appen, an Australian company that has helped train many of Alphabet’s artificial intelligence products including the AI chatbot Bard.

Appen announced over the weekend that Alphabet notified them it will end all contracts effective March 19th. This is a massive blow to Appen, as Alphabet business accounts for around one-third of its total revenue.

Appen specializes in providing training data to tech firms to improve AI systems. It has helped train AI models for Microsoft, Apple, Meta, Amazon, Nvidia and others in addition to Alphabet. But the loss of the Alphabet contracts removes a huge chunk of its business.

Appen said it had no prior knowledge that Alphabet would end the relationship. The decision will impact thousands of subcontractors that Appen uses to source training data for Alphabet projects.

This termination caps what has been a very difficult stretch for the nearly 30-year-old Appen. The company has lost numerous major customers over the past two years as revenue declined 30% in 2023 and 13% in 2022.

Appen’s share price has also absolutely collapsed after peaking in 2020, falling over 99% from its high. Alphabet’s decision now deals a devastating blow to Appen’s attempts to turnaround the business.

Struggles Pivoting to Generative AI

Much of Appen’s struggles relate to challenges pivoting its offering to the new paradigm of generative AI. Models like ChatGPT and Google’s Bard work very differently than earlier AI systems. They rely more on processing power and less on human-labeled training data.

Former Appen employees said the company’s disjointed organizational structure and lack of quality control has hurt its ability to adapt its data services for generative AI. Appen touted work on search, translations, lidar, and more but large language models operate on a different scale.

For years Appen delivered solid growth supplying training data to Big Tech firms. But its business wasn’t built for the paradigm shift towards generative AI. Companies are spending far more on powerful AI chips from Nvidia and less on data from Appen.

Conflicts with Google

Interestingly, Appen has had public conflicts in the past with its now former major customer Alphabet. In 2019, Google mandated that contractors would have to pay workers at least $15 per hour. Appen did not meet that baseline wage requirement according to letters from some of its workers.

Earlier this year wage increases finally went into effect for Appen contractors working on Google projects like Bard. But other labor issues persisted. In June, Appen faced charges after allegedly firing six workers who spoke out about workplace frustrations.

This history of conflicts, along with Appen’s struggles to adapt to new AI needs, likely contributed to Alphabet’s decision to fully cut ties. The exact rationale remains unclear but the termination speaks to a relationship that was on shaky ground.

What’s Next for Appen

The loss of its Alphabet business leaves Appen in an extremely challenging position. In its filing, Appen said it will focus on managing costs and delivering quality AI training data to customers. But it has lost major customer after major customer in recent years.

Appen noted it will provide more details when it reports full year 2023 results in late February. But make no mistake, this termination represents a huge setback for its turnaround efforts.

For Alphabet, the move enables it to take greater control over how it sources training data and labeling for its AI systems. Relying less on third-party vendors aligns with its plans to invest heavily in developing its internal AI capabilities.

Meanwhile, the saga illustrates the rapid evolutions occurring in the AI sector. Generative models are transforming the field. For legacy players like Appen, adapting to stay relevant is proving enormously difficult.

Sunoco’s Blockbuster $7.3B Acquisition of NuStar to Reshape Energy Landscape

Posted on by [email protected]

The energy sector experienced a major shakeup today as Sunoco LP announced it will acquire NuStar Energy in an all-stock deal valued at approximately $7.3 billion including debt. The blockbuster acquisition aims to create a more diversified and vertically integrated energy company with an expanded footprint across the value chain.

For Sunoco, the deal provides a number of key benefits that will strengthen its operations and financial position. Most notably, it will gain NuStar’s extensive pipeline and storage terminal network which spans over 9,500 miles across the United States. This will provide greater scale and diversification to Sunoco’s current focus on fuel distribution and retail. As pipeline assets generate steady contracted revenues, the acquisition is expected to add stability and predictability to cash flows.

The larger cash flow base will also improve Sunoco’s credit profile and enhance its financial flexibility. This will enable accelerated deleveraging while also supporting steady distribution growth. Management estimates the deal will be immediately accretive to distributable cash flow per unit by 10%+ within three years. Ongoing synergies of $150 million annually will also boost the bottom line.

Vertically integrating NuStar’s transportation and storage activities with Sunoco’s strengths in distribution and retail is another major strategic benefit. This will help optimize operations across the integrated value chain and lead to further efficiency gains over time. Cost savings are forecasted at $50 million per year.

For the energy sector overall, the deal also has important implications. The combined entity will control critical infrastructure delivering refined products across the United States. With its expanded footprint, Sunoco will play an even more pivotal role ensuring energy supplies are reliably transported to end-users nationwide.

The acquisition also arrives at a challenging time for the industry. Many energy companies are facing pressure from the transition towards renewable power. By combining forces, Sunoco and NuStar can cut costs, leverage their size and scale, and invest in new growth opportunities. This will ultimately strengthen their competitiveness and staying power.

However, the deal does raise some regulatory concerns. With its extensive control over pipelines and storage capacity, the merged company could potentially restrict competitors’ access. Watchdogs will want to ensure open access at fair rates. Still, management emphasized the acquisition will have a positive financial outlook and support continued distribution growth. This should benefit both sets of unitholders if the deal is approved as expected.

Looking ahead, the acquisition positions Sunoco and NuStar to play a pivotal role in the future of US energy infrastructure. Their integrated network will be crucial for delivering traditional and renewable fuels as the industry evolves. With enhanced financial strength and flexibility, the combined giants now have greater capacity to adapt and seize new opportunities in the years ahead.

Take a look at Noble Capital Markets’ Senior Research Analyst Michael Heim’s coverage universe to take a look at some emerging growth energy companies.

No Recession in Sight for 2024, Say Davos Attendees

Posted on by [email protected]

The annual World Economic Forum concluded on Friday in Davos, Switzerland, after a week of insight from some of the biggest names in business and politics. One of the main takeaways was optimism about avoiding a recession in the U.S. this year, despite ongoing economic concerns.

Most experts and executives see steady growth continuing in 2024, believing the economy remains on solid footing. Reasons for their confidence include potential interest rate cuts by the Federal Reserve in coming months, which could further stimulate economic activity. Consumer confidence has also been rising, suggesting households are eager to keep spending. Barring any major global crises, these factors have led to consensus that a downturn is unlikely in the next year.

The optimism comes as a breath of fresh air after massive disruption from the pandemic in recent years. However, other parts of the world are facing greater struggles. China in particular is dealing with slower growth, which prompted officials to reveal at Davos that their GDP expanded by just 5.2% in 2023. That’s down significantly from the 6-7% range China was averaging pre-pandemic.

Reasons for the slowdown include an ongoing semiconductor trade battle with the U.S. that is hurting tech manufacturing. China is also losing foreign direct investment as companies eye other Asian markets with friendlier business climates. The country recently lost its spot as the world’s most populous to rival India as well. With these challenges mounting, China appears eager for overseas capital to help spur its economy. Its officials breaking precedent to announce 2023 GDP numbers hints at this thirst for foreign money.

While China scrambles, Davos remains as popular as ever, albeit with some growing pains. Several regular attendees commented that the city is having infrastructure troubles keeping up with swarming conferences like the World Economic Forum. Traffic jams of shuttles and Ubers have become constant as hotels fill up. Local government officials apparently can’t even expense rooms anymore due to astronomical prices driven by demand.

This disruption didn’t stop high-level conversations on major themes like technology and geopolitics. Artificial intelligence was one of the hottest topics this year, taking over from the crypto hype of 2022. Companies flooded Davos with advertisements for their AI products and services. Headliners like will.i.am spoke enthusiastically about AI’s potential, announcing plans for a new podcast co-hosted with an AI companion.

But among the boosterism were voices urging calm and perspective. Sam Altman of OpenAI said AI will “change the world much less than we all think.” He noted how companies are using AI as a collaborative tool alongside human employees, rather than replacing them outright. Such measured takes may ease fears about mass job losses from automation. Job postings remain high in most countries, signaling an ongoing need for human skills and oversight.

While AI took center stage this year, some pressing geopolitical matters received surprisingly little airtime. The conflict between Israel and Hamas was rarely discussed, despite its global significance. Some speculate that businesses are wary of irritating stakeholders by speaking out on the polarizing topic. Similar logic may be why few executives criticized the prospect of Donald Trump returning to power. Staying cautiously neutral, however cynical, remains the safest option for profits.

Relatedly, the rise in antisemitism worldwide was a glaring omission in Davos discussions per some attendees. Finding constructive ways to combat prejudice could have been a valuable session. But the lack of debate on this and other divisive issues speaks to a gathering that ultimately caters to the global elite.

AI and recession talk make for good business panel chatter, but taking on discrimination may be beyond Davos’s comfort zone. As the conference’s popularity increases however, pressure may mount to address the most vital social issues of the day rather than sidestep them. Navigating that tension will be key to keeping Davos a premiere gathering of thought leaders.

For now, the World Economic Forum remains sold out and buzzing. Its reputation seems secure even as conversations gravitate toward the safest corporate ground. But avoiding the divides splintering society risks making Davos an echo chamber detached from reality. If it wants to keep its relevance, future forums may need to push attendees out of their comfort zones.

Homebuyers Get a Break as Mortgage Rates Hit 7-Month Low

Posted on by [email protected]

Mortgage rates fell to their lowest level in seven months this past week, providing a glimmer of hope for homebuyers who have been sidelined by high borrowing costs.

The average rate on a 30-year fixed mortgage dropped to 6.60% according to Freddie Mac, down from a recent peak of nearly 8% in October 2023. While still high historically, the retreat back below 7% could draw more prospective homebuyers back into the market.

The dip in rates comes as the housing market is showing early signs of a potential turnaround after a dismal 2023. Home sales plunged nearly 18% last year as surging mortgage rates and stubbornly high prices made purchases unaffordable for many.

But January has seen some positive signals emerge. More homes are coming up for sale as sellers who waited out 2023 finally list their properties. Real estate brokerage Redfin reported a 9% annual increase in inventory in January, the first year-over-year gain since 2019.

At the same time, buyer demand is also perking back up with the improvement in affordability. Mortgage applications jumped 10% last week compared to the prior week according to the Mortgage Bankers Association. While purchase apps remain below year-ago levels, the turnaround suggests buyers are returning.

“If rates continue to ease, MBA is cautiously optimistic that home purchases will pick up in the coming months,” said Joel Kan, MBA’s Vice President of economic and industry forecasting.

The increase in supply and demand has some experts predicting the market may be primed for a rebound in the spring home shopping season. But whether the inventory can satisfy purchaser interest remains uncertain.

“As purchase demand continues to thaw, it will put more pressure on already depleted inventory for sale,” noted Freddie Mac Chief Economist Sam Khater.

Homebuilders have pulled back sharply on new construction as sales slowed over the past year. And many current owners are still hesitant to sell with mortgage rates on their existing homes likely much lower than what they could get today. That leaves the total number of homes available for sale still historically lean.

Nonetheless, agents are reporting more bidding wars again for the limited inventory available in some markets. While not at the frenzied pace of 2022, competition for the right homes is heating up. Experts say interested buyers may want to start making offers now before the selection gets picked over.

“I’m advising house hunters to start making offers now because the market feels pretty balanced,” said Heather Mahmood-Corley, a Redfin agent. “With activity picking up, I think prices will rise and bidding wars will become more common.”

The driver of the downturn in rates since late last year has been an overall cooling of inflation pressures. The Federal Reserve pushed the 30-year fixed mortgage above 7% for the first time in over 20 years with its aggressive interest rate hikes aimed at taming inflation.

But evidence is mounting that the Fed’s policy actions are having the desired effect. Consumer price increases have steadily moderated from 40-year highs last summer. The slower inflation has allowed the central bank to reduce the size of its rate hikes.

Markets now expect the Fed to lift its benchmark rate 0.25 percentage points at its next meeting, a smaller move compared to the 0.50 and 0.75 point hikes seen last year. The slower pace of increases has taken pressure off mortgage rates.

However, the Fed reiterated it plans to keep rates elevated for some time to ensure inflation continues easing. Most experts do not foresee the central bank cutting interest rates until 2024 at the earliest. That means mortgage rates likely won’t fall back to the ultra-low levels seen during the pandemic for years.

But for homebuyers who can manage the higher rates, the recent pullback provides some savings on monthly payments. On a $300,000 loan, the current average 30-year rate would mean about $140 less in the monthly mortgage bill versus the fall peak above 8%.

While housing affordability remains strained by historical standards, some buyers are jumping in now before rates potentially move higher again. People relocating or needing more space are finding ways to cope with the increased costs.

With some forecasts calling for home prices to edge lower in 2024, this year could provide an opportunity for buyers to get in after sitting out 2023’s rate surge. It may be a narrow window however. If demand accelerates faster than supply, the competition and price gains could return quickly.

Jobless Claims Hit Lowest Level Since September 2022 as Labor Market Defies Fed

Posted on by [email protected]

The U.S. job market continues to show resilience despite the Federal Reserve’s efforts to cool economic growth, according to new data released Thursday. Initial jobless claims for the week ending January 13 fell to 187,000, the lowest level since September of last year.

The decline in claims offers the latest evidence that employers remain reluctant to lay off workers even as the Fed raises interest rates to curb demand. The total marked a 16,000 drop from the previous week and came in well below economist forecasts of 208,000.

“Employers may be adding fewer workers monthly, but they are holding onto the ones they have and paying higher wages given the competitive labor market,” said Robert Frick, corporate economist at Navy Federal Credit Union.

The surprising strength comes even as the Fed has lifted its benchmark interest rate seven times in 2023 from near zero to a range of 4.25% to 4.50%. The goal is to dampen demand across the economy, particularly the red-hot job market, in order to bring down uncomfortably high inflation.

In addition to the drop in claims, continuing jobless claims for the week ending January 6 also declined by 26,000 to 1.806 million. That figure runs a week behind the headline number and likewise came in below economist estimates.

The resilience in the labor market comes even as broader economic activity shows signs of cooling. In its latest Beige Book report, the Fed noted that the economy has seen “little or no change” since late November.

Housing markets are a key area feeling the pinch from higher borrowing costs. The Fed summary showed residential real estate activity constrained by rising mortgage rates. Still, there were some green shoots in Thursday’s housing starts data.

Building permits, a leading indicator of future home construction, rose 1.9% in December to 1.495 million. That exceeded economist forecasts of 1.48 million permits. Actual housing starts declined 4.3% to 1.46 million, but still topped estimates calling for 1.43 million.

“The prospects of future easing from the Fed were raising hopes that the pace could accelerate,” the original article noted about housing.

Outside of housing, manufacturing activity in the Philadelphia region contracted again in January, though at a slightly slower pace. The Philly Fed’s index rose to -10.6 this month from -12.8 in December. Readings below zero indicate shrinking activity.

The survey’s gauge of employment at factories in the region also remained negative, though it improved to -1.8 from -7.4 in December. Overall, the Philly Fed report showed declining orders, longer delivery times, and falling inventories.

On inflation, the prices paid index within the survey fell to 43.4 from 51.8 last month. That indicates some easing of cost pressures for manufacturers in the region. The prices received or charged index also ticked lower.

The inflation figures align with the Fed’s latest nationwide look at the economy. The central bank’s Beige Book noted signs of slowing wage growth and easing price pressures. That could give the Fed cover to dial back the pace of interest rate hikes at upcoming meetings this year.

But policymakers also reiterated they plan to keep rates elevated for some time to ensure inflation continues cooling toward the 2% target. Markets still expect the Fed to lift rates again at both its February and March gatherings, albeit by smaller increments of 25 basis points.

With inflation showing increasing signs of moderating from four-decade highs, the focus turns to how much the Fed’s actions will slow economic growth. Thursday’s report on jobless claims hints the labor market remains on solid ground for now.

Employers added over 200,000 jobs per month on average in 2023, well above the pace needed to keep up with population growth. And the unemployment rate ended the year at 3.5%, matching a 50-year low first hit in September.

While job gains are expected to downshift in 2024, the claims report suggests employers are not rushing to cut staff yet. How long the resilience lasts as interest rates remain elevated and growth slows remains to be seen.

For the Fed, it will be a delicate balance between cooling the economy just enough to rein in inflation, without causing substantial job losses or triggering a recession. How well they thread that needle will be closely watched in 2024.

Treasury Yields Spike on Solid Retail Figures, Stocks Pull Back

Posted on by [email protected]

U.S. stocks slumped on Wednesday as Treasury yields climbed following better-than-expected December retail sales. The data signals ongoing economic strength, prompting investors to temper hopes for an imminent Fed rate cut.

The S&P 500 dropped 0.47% to an over one-week low of 4,743, while the Dow shed 0.01% to hit a near one-month low of 37,357. The tech-heavy Nasdaq fared worst, sinking 0.79% to 14,826, its lowest level in a week.

Driving the declines was a surge in the 10-year Treasury yield, which topped 4.1% today – its highest point so far in 2024. The benchmark yield has been rising steadily this year as the Fed maintains its hawkish tone. Higher yields particularly pressured rate-sensitive sectors like real estate, which fell 1.8% for its worst day in a month.

The catalyst behind rising yields was stronger-than-forecast December retail sales. Despite lingering inflation, sales rose 1.4% versus estimates of just 0.1%, buoyed by holiday discounts and robust auto demand. The robust spending highlights the continued resilience of the U.S. economy amidst Fed tightening.

This data substantially dampened investor hopes of the Fed cutting rates as soon as March. Before the report, markets were pricing in a 55% chance of a 25 basis point cut next month. But expectations sank to just 40% after the upbeat sales print.

Traders have been betting aggressively on rate cuts starting in Q2 2024, while the Fed has consistently pushed back on an imminent policy pivot. Chair Jerome Powell stated bluntly last week that “the time for moderating rate hikes may come as soon as the next meeting or meetings.”

“The market is recalibrating its expectations for rate cuts, but I don’t think that adjustment is completely over,” said Annex Wealth Management’s Brian Jacobsen. “A tug-of-war is playing out between what the Fed intends and what markets want.”

Further weighing on sentiment, the CBOE Volatility Index spiked to its highest level in over two months, reflecting anxiety around the Fed’s path. More Fedspeak is due this week from several officials and the release of the Beige Book economic snapshot. These could reinforce the Fed’s resolute inflation fight and keep downward pressure on stocks.

In company news, Tesla shares dropped 2.8% after the electric vehicle leader slashed Model Y prices in Germany by roughly 15%. This follows discounts in China last week as signs of softening demand grow. The price cuts hit Tesla’s stock as profit margins may come under pressure.

Major banks also dragged on markets after Morgan Stanley plunged 2% following earnings. The investment bank flagged weak trading activity and deal-making. Peer banks like Citi, Bank of America and Wells Fargo slid as a result.

On the upside, Boeing notched a 1.4% gain as it cleared a key milestone regarding 737 MAX inspections. This allows the aircraft to reenter service soon, providing a boost to the embattled plane maker.

But market breadth overall skewed firmly negative, with decliners swamping advancers by a 3-to-1 ratio on the NYSE. All 11 S&P 500 sectors finished in the red, underscoring the broad risk-off sentiment.

With the Fed hitting the brakes on easy money, 2024 is shaping up to be a far cry from the bull market of 2021-2022. Bouts of volatility are likely as policy settles into a restrictive posture. For investors, focusing on quality companies with pricing power and adjusting rate hike expectations continue to be prudent moves this year.

Spirit Airlines Stock Slides After Regulators Block JetBlue Merger

Posted on by [email protected]

Shares of low-cost carrier Spirit Airlines plunged a staggering 47% on Tuesday after a federal judge ruled to block the proposed $3.8 billion acquisition by JetBlue Airways. The decision reignited antitrust concerns surrounding consolidation in the airline industry and delivered a major setback to the merger partners.

Judge Leo Sorokin of the U.S. District Court in Massachusetts sided with the Justice Department, which sued earlier this year to halt the deal between the two discount airlines. Regulators argued the merger would lead to higher fares, fewer choices, and reduced competition – particularly impacting budget-conscious leisure travelers.

In his ruling, Sorokin agreed the combination of JetBlue and Spirit would substantially reduce competition in major metropolitan areas and lead to dominant market power on hundreds of routes. Evidence also suggested the merger was likely to raise base fares above pre-merger levels, contradicting the airlines’ claims that the deal would actually lower costs for consumers.

The Justice Department applauded the decision, stating it protected the interests of millions of air travelers against the threat of increased prices and reduced options. The Biden administration has taken a tougher stance on antitrust issues across industries like tech and healthcare. Blocking this airline deal marked the first time in over 20 years regulators successfully halted a major U.S. carrier merger.

JetBlue and Spirit responded with disappointment, saying they disagree with the judge’s rationale and are evaluating their legal options. Previously, the carriers contended combining forces would fuel competition with larger legacy airlines and drive down airfares. But regulators argued JetBlue’s Northeast Alliance with American Airlines already gave the company substantial market power.

For Spirit, the failed acquisition is a crushing blow after months in limbo. The ultra-low cost airline initially agreed to merge with fellow discounter Frontier Airlines before JetBlue stepped in with a higher bid. Now, Spirit finds itself alone again after the about-face regulators delivered.

The collapsed deal and renewed antitrust scrutiny sent Spirit’s stock price into a nosedive. Shares cratered from Friday’s close of $19.66 to around $10.40 on Tuesday after the ruling. The 47% single-day wipeout vaporized over $1.4 billion in market value. Investors are surely questioning what’s next for the budget carrier without an imminent buyer or partner.

The blocked merger also casts uncertainty over ongoing consolidation in the travel and tourism sector. Many investors had bet on further airline combinations to drive efficiency and shareholder returns. With regulators now throwing up roadblocks, the appetite for large-scale airline deals could diminish. That may leave some carriers struggling to gain scale and keep pace with leading players like Delta and American.

Broader travel stocks also felt the tremor of the scuttled Spirit-JetBlue tie-up. Shares of Hawaiian Holdings, involved in a proposed merger with Alaska Air, fell nearly 2% Tuesday afternoon amid the uncertain regulatory environment. Cruise operators like Norwegian and Royal Caribbean slid as much as 5%, potentially signaling dampened outlooks for leisure sector combinations.

Potentially compounding Spirit’s challenges, competitor Frontier Airlines could come back to the table with a renewed merger proposal now that JetBlue is sidelined. Spirit already expended time and resources negotiating with Frontier last year. More uncertainty around consolidation could further destabilize the airline at a precarious moment.

Looking ahead, Spirit and JetBlue still have avenues to continue the legal fight. They could appeal the decision or take their arguments directly to regulators for another look. But after the Justice Department’s strong stance earlier in the case, the odds of overturning the ruling remain long.

For now, the blocked acquisition marks a setback in the wave of consolidation that has swept the U.S. airline industry over the past two decades. Major carriers will be wary of attempting large mergers and risking similar antitrust opposition. While the Biden administration succeeded in halting this particular deal, ongoing fragmentation may not solve the lack of competition in air travel markets across America.

Take a look at Travelzoo (TZOO), an exclusive travel membership that provides travel, entertainment, and lifestyle experiences.